Amro Albanna, CEO of Aditxt, Inc., was recently interviewed by Benzinga.
Aditxt is an innovation platform commercializing promising biotechnologies with a focus on monitoring and modulating the immune system. The company says it aims to “Make Promising Innovations Possible Together."
Aditxt's portfolio includes Adimune, Inc., which is developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, and other disorders, and Adivir, Inc. which is focused on identifying and commercializing new ways to treat infectious diseases.
